Might be hard to buy out the company as i think majority is held fairly tightly?
Pharmas may do partnership for either HD or AL. I think they may wait until final year results to see if brain atrophy reduction becomes significant. If is does, you have an AL drug and a HD drug in my opinion.
I guess it depends on how desperate they are to beat each other to the potential of MPACS or if they see potential in MPACS, on when they might step in.
No doubt PBT management would be looking for a big guy to fund the next stage of drug development.
partnership chances, page-2
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $9.051K | 1.899M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 61886501 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29700836 | 14 |
View Market Depth
| Last trade - 10.23am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 175000 | ||
| Last updated 14.19pm 04/06/2024 ? | |||||
| ATH (ASX) Chart |